Sequoia Biotech Consulting’s Post

Launch Excellence is critical to recognizing the commercial opportunity of your asset. Having the right resources and tools is necessary for effective Launch Excellence. Come join to see how you can optimize or inflect your launch planning and management!

What is the most important aspect when it comes to choosing a development partner? There has been some coverage in the press recently about pharma and biotech organisations favouring midsize contract research organisations (CROs), but we think there are multiple important factors when choosing a development partner. In this blog, we share why our clients repeatedly choose us. https://lnkd.in/getNYvRu

Embarking on the journey from research and development to commercial operations is a transformative phase for biotech companies. It requires a strategic shift in mindset, as well as a comprehensive approach to address the unique challenges of first-time product launches. These emerging biotechs hold the promise of making a meaningful impact on patients' lives, targeting underserved conditions and areas of high unmet need. By embracing innovative strategies, leveraging digital solutions, and fostering a patient-centric culture, they have the opportunity to reshape the industry and drive positive change. Together, we can accelerate the transformation of healthcare and bring groundbreaking treatments to those who need them most. #biotech #development #research #mindset #transformation #nexushiresolutions

While M&A activity has seen a general slowdown recently, the life sciences sector is breaking the mold! According to Dealogic, there's been a remarkable 13% growth in the number of deals, as highlighted in the latest study by McKinsey & Company. What's noteworthy is the focus on smaller transactions in both MedTech and Pharma. In pharma, it's all about replenishing the R&D pipeline and fast-tracking new drug launches. Meanwhile, in MedTech, the race is on to digitize product portfolios, a crucial move in the evolving landscape of connected healthcare ecosystems. But here's the twist – these changing M&A strategies bring significant challenges. Acquired companies are often talent-rich, highly innovative, and boast a unique culture. Key individuals mostly value agility, quick decision-making, and an entrepreneurial spirit. Preserving this dynamic requires a nuanced integration approach. The key is to limit functional and technology synergies to the essentials, instead placing a strong emphasis on data and knowledge sharing. 🌐💡 #LifeSciences #MandA #Innovation #DigitalTransformation #SmartPMI Prinz & Partners LLP

Join Biotech CEOs and COO leaders on July 19th at 11am ET | 5pm CET for a #McKinseyOnBiotech webinar. In this session, we will focus on the importance of a successful #Launch strategy for Biotech companies moving from clinical to commercial stages.   Follow this link to register for the session: https://cvent.me/VKA9n8   #Biotech leaders and McKinsey experts will discuss the latest trends affecting the first launchers and provide insights around the level of investment needed, activities, cultural, and capability shifts that are required in a successful launch.

LS friends, please find link to a short insight piece on trends and tips for navigating mergers and acquisitions (M&A) in the life sciences sector. Deals in the life sciences sector have characteristics not typically seen in more traditional M&A. Deals often involve negotiating around complexities associated with both the unique nature of assets of life sciences companies and the unique industry ecosystem that brings these assets to life. Innovations—be they to drugs or medical equipment—can take years to develop and are not always guaranteed to succeed in the various clinical trial stages. These innovations can also involve multiple stakeholders from academic institutions, hospitals, startups, and established companies, creating a complex web of ownership issues, competing interests, and priorities. #MLLifeSci, #wearemorganlewis, #biotechnology

Today, 66% of biopharma change initiatives failed within the first year (according to the Harvard Business Review). Why? From our experience, changes within large organizations can be just as exciting as they are daunting. Whether it's a merger, launch, or cultural shift, your change initiative will most likely fail. We can fight the odds by implementing single sources of truth, internal campaigns, and deep alignment between all levels of your company — helping you drive change while we drive your team. Learn more at https://lnkd.in/gSUAhumZ.

While M&A activity has seen a general slowdown recently, the life sciences sector is breaking the mold! According to Dealogic, there's been a remarkable 13% growth in the number of deals, as highlighted in the latest study by McKinsey & Company. What's noteworthy is the focus on smaller transactions in both MedTech and Pharma. In pharma, it's all about replenishing the R&D pipeline and fast-tracking new drug launches. Meanwhile, in MedTech, the race is on to digitize product portfolios, a crucial move in the evolving landscape of connected healthcare ecosystems. But here's the twist – these changing M&A strategies bring significant challenges. Acquired companies are often talent-rich, highly innovative, and boast a unique culture. Key individuals mostly value agility, quick decision-making, and an entrepreneurial spirit. Preserving this dynamic requires a nuanced integration approach. The key is to limit functional and technology synergies to the essentials, instead placing a strong emphasis on data and knowledge sharing. 🌐💡 #LifeSciences #mergerandacquisition  #Innovation #DigitalTransformation #SmartPMI Prinz & Partners LLP https://lnkd.in/gdxK5Z3y